End stage and chronic kidney disease: associations with renal cancer
- PMID: 22649783
- PMCID: PMC3355889
- DOI: 10.3389/fonc.2012.00028
End stage and chronic kidney disease: associations with renal cancer
Abstract
There is a well known association between end stage renal disease and the development of kidney cancer in the native kidney of patients requiring renal replacement therapy. There is now emerging evidence that lesser degrees of renal insufficiency (chronic kidney disease, CKD) are also associated with an increased likelihood of cancer in general and kidney cancer in particular. Nephropathological changes are commonly observed in the non-tumor bearing portions of kidney resected at the time of partial and radical nephrectomy (RN). In addition, patients with renal cancer are more likely to have CKD at the time of diagnosis and treatment than the general population. The exact mechanism by which renal insufficiency transforms normal kidney cells into tumor cells is not known. Possible mechanisms include uremic immune inhibition or increased exposure to circulating toxins not adequately cleared by the kidneys. Surgeons managing kidney tumors must have an increased awareness of their patient's renal functional status as they plan their resection. Kidney sparing approaches, including partial nephrectomy (PN) or active surveillance in older and morbidly ill patients, can prevent CKD or delay the further decline in renal function which is well documented with RN. Despite emerging evidence that PN provides equivalent local tumor control to RN while at the same time preventing CKD, this operation remains under utilized in the United States and abroad. Increased awareness of the bi directional relationship between kidney function and kidney cancer is essential in the contemporary management of kidney cancer.
Keywords: chronic kidney disease; kidney cancer; partial nephrectomy; radical nephrectomy; renal insufficiency.
Similar articles
-
Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease.Int Urol Nephrol. 2016 Sep;48(9):1421-7. doi: 10.1007/s11255-016-1317-9. Epub 2016 May 18. Int Urol Nephrol. 2016. PMID: 27193433
-
Comprehensive Management of Renal Masses in Solitary Kidneys.Eur Urol Oncol. 2023 Feb;6(1):84-94. doi: 10.1016/j.euo.2022.11.004. Epub 2022 Dec 12. Eur Urol Oncol. 2023. PMID: 36517406
-
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.Eur Urol. 2013 Oct;64(4):600-6. doi: 10.1016/j.eururo.2012.12.023. Epub 2012 Dec 25. Eur Urol. 2013. PMID: 23280319
-
Functional preservation in patients with renal cortical tumors: the rationale for partial nephrectomy.Curr Urol Rep. 2008 Jan;9(1):15-21. doi: 10.1007/s11934-008-0005-4. Curr Urol Rep. 2008. PMID: 18366969 Review.
-
Partial nephrectomy versus radical nephrectomy for cT2 or greater renal tumors: a systematic review and meta-analysis.Minerva Urol Nefrol. 2019 Oct;71(5):435-444. doi: 10.23736/S0393-2249.19.03470-2. Epub 2019 Jul 8. Minerva Urol Nefrol. 2019. PMID: 31287256
Cited by
-
Partial nephrectomy for T3aN0M0 renal cell carcinoma: shall we step forward?Int Braz J Urol. 2017 Sep-Oct;43(5):849-856. doi: 10.1590/S1677-5538.IBJU.2016.0598. Int Braz J Urol. 2017. PMID: 28792193 Free PMC article.
-
Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States.Am J Transplant. 2016 Dec;16(12):3479-3489. doi: 10.1111/ajt.13862. Epub 2016 Jun 23. Am J Transplant. 2016. PMID: 27160653 Free PMC article.
-
Non-neoplastic parenchymal changes in kidney cancer and post-partial nephrectomy recovery of renal function.Int Urol Nephrol. 2015 Sep;47(9):1499-502. doi: 10.1007/s11255-015-1066-1. Epub 2015 Aug 12. Int Urol Nephrol. 2015. PMID: 26265107 Free PMC article.
-
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.J Immunol Res. 2018 Sep 6;2018:2180373. doi: 10.1155/2018/2180373. eCollection 2018. J Immunol Res. 2018. PMID: 30271792 Free PMC article. Review.
-
Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma.Quant Imaging Med Surg. 2020 May;10(5):988-998. doi: 10.21037/qims-19-723. Quant Imaging Med Surg. 2020. PMID: 32489923 Free PMC article.
References
-
- Buell J. F., Gross T. G., Woodle E. S. (2005). Malignancy after transplantation. Transplantation 80, S254–S26410.1097/01.tp.0000186382.81130.ba - DOI - PubMed
LinkOut - more resources
Full Text Sources
Medical